Wasdell Group launches serialisation service
Company will offer compliant products to all markets, including Europe and the US.
The Wasdell Group, a leading outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, has launched its serialisation service ahead of the EU FMD and US DSCSA implementation deadlines.
Following a £2.8 million investment into serialisation capabilities in 2016, the company will offer compliant products to all markets, including Europe and the US, from its sites in Newcastle and Swindon.
Wasdell’s new facility in Ireland, due to open January 2019, will also offer serialisation for all products.
Daniel Tedham, managing director of Wasdell Manufacturing said: ”Wasdell operate on a global scale making the ability to comply with regulations of various markets essential, so we made the choice to invest in our serialisation capabilities very early on.
”As a CMO we handle a huge variety of products that all have specific needs, as well as a customer base of over 250 unique customers who also have their own requirements. It was important that our solution meant we could remain flexible enough to meet these criteria, hence our proactive approach.
”Implementing a solution across multiple lines that need to supply to numerous markets is a challenging process that many companies have underestimated. We wanted to ensure we were ready well ahead of schedule to guarantee that we could effectively support current and future clients with compliance with the EU FMD, US DSCSA and other market regulations.”
As part of its serialisation service, Wasdell will also be able to offer three tier aggregation from carton to pallet to ensure compliance with future changes to regulations.
”Equipping our lines with aggregation capabilities means we are ready to continue supplying products to the US following the 2023 deadline for three-tier parent-child relationships between barcodes and that we can deal with future amends to regulations in other markets.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.